People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cirius Therapeutics, Inc. | — | Biotechnology | Series B | $49.6M | $3.3M | 2018 |
| Lengo Therapeutics, Inc. | — | Pharmaceuticals | Series B | $17.7M | $601.9M | 2020 |
Daniel Estes, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Estes, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Robert Beardsley | 1 | 5 |
| Robert Zerbe | 1 | 5 |
| Robert A. Beardsley | 1 | 4 |
| Mark Olesnavage | 1 | 4 |
| Nilesh Kumar | 1 | 4 |
| Anna Chen | 1 | 3 |
| Elaine Sun | 1 | 3 |
| Daniel Estes | 1 | 3 |
| Steve Bailey | 1 | 2 |
| Michael Jandernoa | 1 | 2 |
| Howard Dittrich | 1 | 2 |
| Robert A Zerbe | 1 | 2 |
| David Van Andel | 1 | 2 |
| Brian Farmer | 1 | 2 |
| Robert Baltera | 1 | 2 |
| Helen Jenkins | 1 | 2 |
| Baltera Bob | 1 | 1 |
| Nilesh Kumar, Ph.D. | 1 | 1 |
| Robert Zerbe, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.